Brief: CANbridge Pharmaceuticals Posts H1 Revenue RMB 44.8 Mln
30/08/2024 24:36
Aug 30 (Reuters) - CANbridge Pharmaceuticals H1 gross margin 65.7%. * H1 adjusted net income RMB -242.5 million * H1 revenue RMB 44.8 million * H1 gross profit RMB 29.4 million
Recent news on CANbridge Pharmaceuticals
See all newsChina's CANbridge Pharmaceuticals H1 revenue rises on Hunterase and Livmarli strength
Brief: CANbridge Pharmaceuticals Posts HY Loss of RMB37.1 MLN
Brief: Canbridge Pharmaceuticals Says Livmarli Obtains NHIA Reimbursement Approval In Taiwan For ALGS And PFIC
Brief: Canbridge Pharmaceuticals Initiates Registration And Launch Preparations For Gaurunning In North African Market
CANbridge Pharmaceuticals jumps as WuXi Biologics buys shares